Patents by Inventor Christian Trötschel

Christian Trötschel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbial Cells Possessing a Reduced Lactose Internalization For Producing an Oligosaccharide
    Publication number: 20240110213
    Abstract: Disclosed are genetically engineered microbial cells for the production of an oligosaccharide of interest, wherein said microbial cells possess a variant of the E. coli lactose permease LacY which exhibits a reduced transport activity for lactose, and methods for producing an oligosaccharide by using said genetically engineered microbial cells.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 4, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Henning Frerigmann, Christian Trötschel, Dirk Wartenberg, Stefan Jennewein
  • Improved Export of Oligosaccharides From Bacterial Cells
    Publication number: 20230304052
    Abstract: Disclosed are genetically-engineered gram-negative bacterial cells for the production of an oligosaccharide of interest, wherein the bacterial cell possesses a saccharide transporter and/or a porin being expressed from a recombinant gene or a deregulated endogenous gene, thereby facilitating the translocation of the oligosaccharide of interest from the cell's cytoplasm into the cell's environment. Also disclosed are methods for producing an oligosaccharide of interest which used said genetically-engineered gram-negative bacterial cells.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 28, 2023
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Markus Englert, Stefan Jennewein, Henning Frerigmann, Katja Parschat, Christian Trötschel
  • PDE III inhibitors for treatment of asymptomatic heart failure
    Patent number: 11413285
    Abstract: A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: August 16, 2022
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE
    Publication number: 20190008862
    Abstract: A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 10, 2019
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • PDE III inhibitors for treatment of asymptomatic heart failure
    Patent number: 10117869
    Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 6, 2018
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
    Patent number: 8980894
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: March 17, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE
    Publication number: 20130203690
    Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleeman, Christian Troetschel, Andrea Vollmar
  • Use of PDE III Inhibitors for the Treatment of Asymptomatic (Occult) Heart Failure
    Publication number: 20100273807
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patents having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having an asymptomatic (occult) heart failure of a patient suffering from asymptomatic heart disease.
    Type: Application
    Filed: July 7, 2010
    Publication date: October 28, 2010
    Inventors: Rainer Kleeman, Christian Troetschel, Andrea Vollmar
  • Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure
    Publication number: 20100035889
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
    Type: Application
    Filed: June 11, 2009
    Publication date: February 11, 2010
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • USE OF PDE III INHIBITORS FOR THE TREAMENT OF ASYMPTOMATIC (OCCULT) HEART FAILURE
    Publication number: 20070112010
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having an asymptomatic (occult) heart failure of a patient suffering from asymptomatic heart disease.
    Type: Application
    Filed: November 14, 2006
    Publication date: May 17, 2007
    Inventors: Rainer Kleeman, Christian Troetschel, Andrea Vollmar